Neurophysiology of Cough Reflex Hypersensitivity
Launched by UNIVERSITY OF MANCHESTER · Sep 14, 2009
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Healthy volunteers inclusion:
- • Over 18 years
- • Measurable cough reflex sensitivity - required as is the primary end-point
- • No current or past history of chronic cough or chronic respiratory disease
- Chronic Cough Patients inclusion:
- • Over 18 years
- • Chronic persistent cough (\> 8 weeks) despite investigation and/or treatment trials for cough variant asthma/post-nasal drip and gastro-oesophageal reflux
- • Normal chest radiograph - primary respiratory cause for cough excluded
- • Normal lung function - primary respiratory cause for cough excluded Measurable cough reflex sensitivity - required as primary end-point
- Exclusion Criteria:
- • Recent upper respiratory tract infection (\<4 weeks) - this can lead to increased sensitivity of the cough reflex which resolves as the infection settles
- • Pregnancy/breast-feeding - unknown effects of oesophageal acid infusion
- • Current smokers or ex-smokers with \< 6 month abstinence or history \> 20 pack years - smoking can alter the sensitivity of the cough reflex
- • Opiate or ACE inhibitor use or centrally acting medication - can alter the cough reflex sensitivity
- • Symptomatic gastro-oesophageal reflux, post-nasal drip or asthma (chronic cough cohort may have been treated for these in the past but cough did not resolve) - these conditions are known to cause cough and alter cough reflex sensitivity
- • Significant ongoing chronic respiratory/cardiovascular/gastro-intestinal/haematological/ neurological/psychiatric illness. We are aiming to recruit healthy volunteers and chronic cough patients who are otherwise healthy
About University Of Manchester
The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, , United Kingdom
Patients applied
Trial Officials
Ashley Woodcock, Prof
Principal Investigator
The University of Manchester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials